Aclaris Therapeutics ACRS
Valuation
Multiples measured against the stock's own five-year history
Around its usual level · 43rd percentile, 5-year average -5.5x
Around its usual level · 60th percentile, 5-year average 3.0x
#4053 of 5329 stocks by PB (1 = cheapest)
Above its usual level · 78th percentile, 5-year average 49.5x
#4947 of 5156 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 3.73 | – | 2.97 | 60% (pricier than usual) | #4053 of 5329 (1 = cheapest) |
| PE | -6.64 | -5.28 | -5.53 | 43% (cheaper than usual) | – |
| PS | 97.13 | 149.76 | 49.55 | 78% (pricier than usual) | #4947 of 5156 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on ACRS.
Sign in to join the discussion.